Annual report
3151.TEDINET S100YDSN
Period2025-04-01 → 2026-03-31
Filed2026-06-19
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥610.5bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥600.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥587.5bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥581.3bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥578.8bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥4.0bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥5.7bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥7.8bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥7.0bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥6.6bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.0bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥11.5bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥10.7bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥7.4bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥7.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.8bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.8bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.8bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥7.5bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥7.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥320.6bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥299.4bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥317.3bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥297.3bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥313.0bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥201.9bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥192.1bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥118.7bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥107.3bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥105.9bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥100.2bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥100.0bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥23.0bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥23.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥19.4bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.1bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥31.1bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥15.1bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥23.2bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥4.8bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥8.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.6bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥3.0bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥7.5bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥3.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.8bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.0bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.0bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥4.4bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.8bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.1bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥8.5bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥152.29 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥149.02 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥115.03 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.69 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.88 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,423.12 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,193.96 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,085.09 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,911.44 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,858.86 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 36.6% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.4% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.0% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.3% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 6.6% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.9% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.7% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 3,871 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 3,756 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 3,705 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 3,719 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 3,754 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥5.6bn | 2025-04-01 → 2026-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥7.7bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥8.8bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.2bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.9bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥4.8bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥6.7bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥4.7bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥6.7bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥7.9bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.4bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.1bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥4.7bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥6.6bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥4.7bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥6.6bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥7.9bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥4.4bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥4.1bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥74.9bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥75.2bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥76.1bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥69.2bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥69.2bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥18.7bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥21.0bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥56.2bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥54.2bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥52.2bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥48.3bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥46.3bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥5.2bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥7.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥97.03 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥134.93 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥156.33 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥83.57 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.04 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥70 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥45 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥42 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥39 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥26 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,162.56 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,123.29 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,039.86 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥931.75 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥868.78 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 75.1% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.1% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.6% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.8% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.9% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.5% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.4% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.8% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.0% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 51,902,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 51,902,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 51,902,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 61,224,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 61,224,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 52 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 52 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 54 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 54 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 62 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 88
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥13.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥13.8bn |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | −¥12.1bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥35m |
| Medicine Wholesalereportable segment | capex | 2025-04-01 → 2026-03-31 | ¥6.0bn |
| Medicine Wholesalereportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥3.4bn |
| Medicine Wholesalereportable segment | employees | at 2026-03-31 | 2509 pure |
| Medicine Wholesalereportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥583.9bn |
| Medicine Wholesalereportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥572.9bn |
| Medicine Wholesalereportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥11.0bn |
| Medicine Wholesalereportable segment | segment assets | at 2026-03-31 | ¥298.9bn |
| Medicine Wholesalereportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥4.9bn |
| Nursing Care Related Rental And Other Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥144m |
| Nursing Care Related Rental And Other Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥274m |
| Nursing Care Related Rental And Other Businessreportable segment | employees | at 2026-03-31 | 697 pure |
| Nursing Care Related Rental And Other Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥7.9bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥5.0bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥2.8bn |
| Nursing Care Related Rental And Other Businessreportable segment | segment assets | at 2026-03-31 | ¥16.1bn |
| Nursing Care Related Rental And Other Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥102m |
| Pharmaceutical Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥15m |
| Pharmaceutical Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥0 |
| Pharmaceutical Businessreportable segment | employees | at 2026-03-31 | 3 pure |
| Pharmaceutical Businessreportable segment | segment assets | at 2026-03-31 | ¥2.2bn |
| Pharmaceutical Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥1.3bn |
| Pharmacy Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥252m |
| Pharmacy Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥183m |
| Pharmacy Businessreportable segment | employees | at 2026-03-31 | 546 pure |
| Pharmacy Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥20.0bn |
| Pharmacy Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥20.0bn |
| Pharmacy Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥12m |
| Pharmacy Businessreportable segment | segment assets | at 2026-03-31 | ¥9.3bn |
| Pharmacy Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥252m |
| Veterinary Drugs Wholesale Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥37m |
| Veterinary Drugs Wholesale Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥20m |
| Veterinary Drugs Wholesale Businessreportable segment | employees | at 2026-03-31 | 116 pure |
| Veterinary Drugs Wholesale Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥12.6bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥12.6bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥0 |
| Veterinary Drugs Wholesale Businessreportable segment | segment assets | at 2026-03-31 | ¥6.1bn |
| Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥304m |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥6.5bn |
| —segment total | depreciation | 2025-04-01 → 2026-03-31 | ¥3.9bn |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥624.3bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥610.5bn |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥13.8bn |
| —segment total | segment assets | at 2026-03-31 | ¥332.7bn |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥4.1bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥13.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥13.5bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | −¥7.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | ¥55m |
| Medicine Wholesalereportable segment | capex | 2024-04-01 → 2025-03-31 | ¥3.0bn |
| Medicine Wholesalereportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥3.2bn |
| Medicine Wholesalereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥575.4bn |
| Medicine Wholesalereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥564.6bn |
| Medicine Wholesalereportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥10.8bn |
| Medicine Wholesalereportable segment | segment assets | at 2025-03-31 | ¥279.4bn |
| Medicine Wholesalereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥5.2bn |
| Nursing Care Related Rental And Other Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥120m |
| Nursing Care Related Rental And Other Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥248m |
| Nursing Care Related Rental And Other Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥7.3bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥4.6bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥2.7bn |
| Nursing Care Related Rental And Other Businessreportable segment | segment assets | at 2025-03-31 | ¥12.8bn |
| Nursing Care Related Rental And Other Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥78m |
| Pharmacy Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥88m |
| Pharmacy Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥157m |
| Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥19.6bn |
| Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥19.6bn |
| Pharmacy Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥12m |
| Pharmacy Businessreportable segment | segment assets | at 2025-03-31 | ¥9.4bn |
| Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥251m |
| Veterinary Drugs Wholesale Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥3m |
| Veterinary Drugs Wholesale Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥18m |
| Veterinary Drugs Wholesale Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥11.6bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥11.6bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥0 |
| Veterinary Drugs Wholesale Businessreportable segment | segment assets | at 2025-03-31 | ¥5.8bn |
| Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥314m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥3.2bn |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥3.7bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥613.9bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥600.4bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥13.5bn |
| —segment total | segment assets | at 2025-03-31 | ¥307.3bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥5.7bn |
| Medicine Wholesalereportable segment | employees | at 2026-03-31 | 52 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,128
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of female directors and other officers | FilingDateInstant | 3 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.25 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000MuraiTaisukeMember | 111000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000IchijoTakeshiMember | 114000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000IguchiToshiyukiMember | 9000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000SuzukiMitsunaoMember | 166000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000SuzukiKoichiroMember | 1029000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000KitaIsaoMember | 9000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000OnokiKiekoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000KatsuraJunMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000TsugitaMasamiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000TakahashiKiharuMember | 3000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000NishitaniTsuyoshiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000IwataMamikoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 1441000 | |
| Audit fees reporting company | Prior1YearDuration | 17000000 | JPY |
| Non audit fees reporting company | Prior1YearDuration | 9000000 | JPY |
| Audit fees reporting company | CurrentYearDuration | 19000000 | JPY |
| Non audit fees reporting company | CurrentYearDuration | 9000000 | JPY |
| Audit fees consolidated subsidiaries | Prior1YearDuration | 62000000 | JPY |
| Non audit fees consolidated subsidiaries | Prior1YearDuration | － | JPY |
| Audit fees consolidated subsidiaries | CurrentYearDuration | 65000000 | JPY |
| Non audit fees consolidated subsidiaries | CurrentYearDuration | － | JPY |
| Audit fees total | Prior1YearDuration | 79000000 | JPY |
| Non audit fees total | Prior1YearDuration | 9000000 | JPY |
| Audit fees total | CurrentYearDuration | 84000000 | JPY |
| Non audit fees total | CurrentYearDuration | 9000000 | JPY |
| Audit fees reporting company network firms | Prior1YearDuration | － | JPY |
| Non audit fees reporting company network firms | Prior1YearDuration | － | JPY |
| Audit fees reporting company network firms | CurrentYearDuration | － | JPY |
| Non audit fees reporting company network firms | CurrentYearDuration | － | JPY |
| Audit fees consolidated subsidiaries network firms | Prior1YearDuration | － | JPY |
| Non audit fees consolidated subsidiaries network firms | Prior1YearDuration | － | JPY |
| Audit fees consolidated subsidiaries network firms | CurrentYearDuration | － | JPY |
| Non audit fees consolidated subsidiaries network firms | CurrentYearDuration | 2000000 | JPY |
| Audit fees total network firms | Prior1YearDuration | － | JPY |
| Non audit fees total network firms | Prior1YearDuration | － | JPY |
| Audit fees total network firms | CurrentYearDuration | － | JPY |
| Non audit fees total network firms | CurrentYearDuration | 2000000 | JPY |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingAuditAndSupervisoryCommitteeMembersAndOutsideDirectorsMember | － | JPY |
| Base remuneration remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingAuditAndSupervisoryCommitteeMembersAndOutsideDirectorsMember | － | JPY |
| Bonus remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingAuditAndSupervisoryCommitteeMembersAndOutsideDirectorsMember | － | JPY |
| Retirement benefits remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingAuditAndSupervisoryCommitteeMembersAndOutsideDirectorsMember | － | JPY |
| Share awards remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingAuditAndSupervisoryCommitteeMembersAndOutsideDirectorsMember | － | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingAuditAndSupervisoryCommitteeMembersAndOutsideDirectorsMember | － | |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsAppointedAsAuditAndSupervisoryCommitteeMembersExcludingOutsideDirectorsMember | － | JPY |
| Base remuneration remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsAppointedAsAuditAndSupervisoryCommitteeMembersExcludingOutsideDirectorsMember | － | JPY |
| Bonus remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsAppointedAsAuditAndSupervisoryCommitteeMembersExcludingOutsideDirectorsMember | － | JPY |
| Retirement benefits remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsAppointedAsAuditAndSupervisoryCommitteeMembersExcludingOutsideDirectorsMember | － | JPY |
| Share awards remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsAppointedAsAuditAndSupervisoryCommitteeMembersExcludingOutsideDirectorsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |